SymBio Pharmaceuticals Limited (4582.T)
JPY 154.0
(-1.28%)
JPY 154.0
(-1.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.22 Billion JPY | -7.34% |
| 2022 | 5.63 Billion JPY | 17.81% |
| 2021 | 4.78 Billion JPY | -10.96% |
| 2020 | 5.37 Billion JPY | 4.0% |
| 2019 | 5.16 Billion JPY | 34.93% |
| 2018 | 3.82 Billion JPY | -23.09% |
| 2017 | 4.97 Billion JPY | 64.23% |
| 2016 | 3.03 Billion JPY | -3.3% |
| 2015 | 3.13 Billion JPY | 71.3% |
| 2014 | 1.82 Billion JPY | -8.44% |
| 2013 | 1.99 Billion JPY | -12.85% |
| 2012 | 2.29 Billion JPY | -15.85% |
| 2011 | 2.72 Billion JPY | 49.36% |
| 2010 | 1.82 Billion JPY | 30.41% |
| 2009 | 1.39 Billion JPY | -6.55% |
| 2008 | 1.49 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.27 Billion JPY | -12.67% |
| 2024 Q3 | 1.51 Billion JPY | 5.68% |
| 2024 Q2 | 1.43 Billion JPY | 12.53% |
| 2023 Q4 | 1.46 Billion JPY | 18.33% |
| 2023 Q1 | 1.19 Billion JPY | -32.22% |
| 2023 FY | 5.22 Billion JPY | -7.34% |
| 2023 Q2 | 1.33 Billion JPY | 11.65% |
| 2023 Q3 | 1.23 Billion JPY | -7.08% |
| 2022 Q4 | 1.75 Billion JPY | 41.84% |
| 2022 FY | 5.63 Billion JPY | 17.81% |
| 2022 Q1 | 1.38 Billion JPY | 19.47% |
| 2022 Q2 | 1.24 Billion JPY | -10.07% |
| 2022 Q3 | 1.23 Billion JPY | -0.75% |
| 2021 Q3 | 1.15 Billion JPY | -7.79% |
| 2021 Q1 | 1.22 Billion JPY | -24.66% |
| 2021 FY | 4.78 Billion JPY | -10.96% |
| 2021 Q4 | 1.16 Billion JPY | 0.93% |
| 2021 Q2 | 1.24 Billion JPY | 2.35% |
| 2020 FY | 5.37 Billion JPY | 4.0% |
| 2020 Q2 | 1.08 Billion JPY | -0.86% |
| 2020 Q1 | 1.08 Billion JPY | 2.11% |
| 2020 Q3 | 1.58 Billion JPY | 46.57% |
| 2020 Q4 | 1.61 Billion JPY | 2.31% |
| 2019 Q3 | 1.55 Billion JPY | 16.05% |
| 2019 Q2 | 1.33 Billion JPY | 11.19% |
| 2019 FY | 5.16 Billion JPY | 34.93% |
| 2019 Q4 | 1.06 Billion JPY | -31.36% |
| 2019 Q1 | 1.2 Billion JPY | 20.82% |
| 2018 Q4 | 997.21 Million JPY | 6.79% |
| 2018 FY | 3.82 Billion JPY | -23.09% |
| 2018 Q1 | 964.02 Million JPY | 21.19% |
| 2018 Q2 | 933.91 Million JPY | -3.12% |
| 2018 Q3 | 933.79 Million JPY | -0.01% |
| 2017 Q3 | 2.43 Billion JPY | 148.29% |
| 2017 FY | 4.97 Billion JPY | 64.23% |
| 2017 Q1 | 764.21 Million JPY | -25.11% |
| 2017 Q2 | 981.55 Million JPY | 28.44% |
| 2017 Q4 | 795.48 Million JPY | -67.36% |
| 2016 FY | 3.03 Billion JPY | -3.3% |
| 2016 Q4 | 1.02 Billion JPY | 29.84% |
| 2016 Q1 | 574.91 Million JPY | -67.18% |
| 2016 Q2 | 649.81 Million JPY | 13.03% |
| 2016 Q3 | 785.99 Million JPY | 20.96% |
| 2015 Q1 | 452.71 Million JPY | -11.2% |
| 2015 Q3 | 452.22 Million JPY | -5.36% |
| 2015 FY | 3.13 Billion JPY | 71.3% |
| 2015 Q4 | 1.75 Billion JPY | 287.39% |
| 2015 Q2 | 477.84 Million JPY | 5.55% |
| 2014 Q3 | 426.74 Million JPY | -4.21% |
| 2014 FY | 1.82 Billion JPY | -8.44% |
| 2014 Q4 | 509.78 Million JPY | 19.46% |
| 2014 Q2 | 445.48 Million JPY | -0.54% |
| 2014 Q1 | 447.9 Million JPY | -15.87% |
| 2013 Q2 | 499.5 Million JPY | 1.52% |
| 2013 Q3 | 474.58 Million JPY | -4.99% |
| 2013 Q4 | 532.41 Million JPY | 12.19% |
| 2013 FY | 1.99 Billion JPY | -12.85% |
| 2013 Q1 | 492 Million JPY | -13.63% |
| 2012 Q3 | 583.76 Million JPY | 9.99% |
| 2012 Q4 | 569.67 Million JPY | -2.41% |
| 2012 FY | 2.29 Billion JPY | -15.85% |
| 2012 Q1 | 609.05 Million JPY | 10.32% |
| 2012 Q2 | 530.76 Million JPY | -12.86% |
| 2011 Q1 | 494 Million JPY | 0.0% |
| 2011 Q2 | 543.18 Million JPY | 9.96% |
| 2011 Q3 | 1.13 Billion JPY | 109.12% |
| 2011 Q4 | 552.07 Million JPY | -51.4% |
| 2011 FY | 2.72 Billion JPY | 49.36% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | 1.82 Billion JPY | 30.41% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | 1.39 Billion JPY | -6.55% |
| 2008 FY | 1.49 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 88.032% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.801% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.037% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 97.357% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -39.78% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 92.042% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 82.007% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.02% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 1.123% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 92.063% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 88.712% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 54.794% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 36.556% |
| Tsumura & Co. | 48.8 Billion JPY | 89.298% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 84.328% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 73.268% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 91.806% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 58.737% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 87.093% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 88.495% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | -25.636% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 12.15% |
| MedRx Co., Ltd | 959 Million JPY | -444.597% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -81.739% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -253.84% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -120.304% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 78.387% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 85.26% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -610.394% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 94.768% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -131.37% |